Skip to main content Accessibility help
  • Cited by 2
  • Print publication year: 2011
  • Online publication date: December 2011

8 - Health-related quality of life assessment in multiple sclerosis

from Section II - Clinical trial methodology


The Food and Drug Administration (FDA) has offered guidance on using health related quality of life (HRQoL) measures to support labeling claims, and the definition of HRQoL has become more systematized. HRQoL measures look at patients' reports of their perceived health in either very general or very particular terms. Utility assessment is an increasingly active area of research in multiple sclerosis (MS). HRQoL data are used for three general purposes: to classify or group patients by levels of disease severity, predict the health of subjects at a future point in time, and as outcome variables. MS-specific HRQoL measures have been included as endpoints in many clinical studies, including some randomized controlled clinical trials. Selection of the most appropriate disease-specific measures by investigators should be based on available validity and reliability data for those measures and the specific questions that the researcher hopes to answer.

Related content

Powered by UNSILO


1. Sackette DL. Evidence-Based Medicine: How to Practice and Teach EBM. New York: Churchill Livingstone, 1997.
2. Medicine Io. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press, 2009.
3.AHRQ. What is comparative effectiveness research? [online]. Available at:
4. Slutsky JR, Clancy CM. Patient-centered comparative effectiveness research: essential for high-quality care. Arch Intern Med 2010; 170:403–4.
5. Rose MR, Weinman J. Quality of life: listen to, change, or shoot the messenger? Neurology 2007; 68:1095–6.
6. Guyatt GH, Jaeschke R, Feeny DH, Patrick DL, Spilker B. Measurements in Clinial Trials: Choosing the Right Approach. In Spilker B, ed. Philadelphia: Lippincott-Raven, 1996:41–8.
7. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis. BMJ (Clin Res Ed) 1997; 314:1580–3.
8. Freeman JA, Langdon DW, Hobart JC, Thompson AJ. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 1999; 52:50–6.
9. Kinkel RP, Conway K, Copperman L, et al. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC: Paralyzed Veterans of America, 1998.
10. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118:622–9.
11. Kaplan RM, Anderson JP, Spilker B. The general heath policy model: an integrated approach. In Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott Raven, 1996:309–22.
12. Kattan MW. Comparing treatment outcomes using utility assessment for health-related quality of life. Oncology 2003; 17:1687– 93.
13.Office of Communications DoDI, Center for Drug Evaluation and Research Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: Food and Drug Administration, December, 2009.
14. Norman GR, Wyrwich KW, Patrick DL. The mathematical relationship among different forms of responsiveness coefficients. Qual Life Res 2007; 16:815–22.
15. Giordano A, Pucci E, Naldi P, et al. Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study. J Neurol Neurosurg Psychiatr 2009; 80:1023–8.
16. Traugott U. Evidence for immunopathogenesis. In: Cook S, ed. Handbook of Multiple Sclerosis. New York: Marcel Dekker, 1990;101–27.
17. World Health O. International Classification of Impairments, Disabilities and Handicaps (ICIDH): A Manual for Classification. Geneva: WHO, 1980.
18. Schipper H, Clinch JJ, Olweny CLM, Spilker. Quality of life studies: definitions and conceptual issues. In Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996:11–24.
19. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9:1259–76.
20. Weeks J. Taking Quality of Life into Account in Health Economics Analysis: National Cancer Institute, 1996.
21. Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Med Care 1989; 27(3 Suppl):S190–204.
22. von Neumann J, Morgenstern O. Theory of Games and Economic Behavior. Princeton: Princeton University Press, 1944.
23. Weinstein MC, Fineberg HV. Clinical Decision Analysis. Philadelphia: W.B. Saunders, 1980.
24. Cole BF, Gelber RD, Goldhirsch A. Cox regression models for quality adjusted survival analysis. Stat Med 1993; 12:975–87.
25. Glasziou PP, Cole BF, Gelber RD, Hilden J, Simes RJ. Quality adjusted survival analysis with repeated quality of life measures. Stat Med 1998; 17:1215–29.
26. Hwang JS, Tsauo JY, Wang JD. Estimation of expected quality adjusted survival by cross-sectional survey. Stat Med 1996; 15:93–102.
27. Shen LZ, Pulkstenis E, Hoseyni M. Estimation of mean quality adjusted survival time. Stat Med 1999; 18:1541–54.
28. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatr 2005; 76:58–63.
29. Kattan MW, Fearn NA, Miles BJ. Time trade-off utility modified to accommodate degenerative and life-threatening conditions. Presented at the 2001 American Medical Informatics Association Symposium, Washington, DC.
30. Bakker C, Rutten-van Molken M, Hidding A, van Doorslaer E, Bennett K, Van Der LS. Patient utilities in ankylosing spondylitis and the association with other outcome measures. J Rheumatol 1994; 21:1298–304.
31. Bennett L, Hamilton R, Neutel CI, Pearson JC, Talbot B. Survey of persons with multiple sclerosis in Ottawa, 1974–75. Can J Public Health 1977; 68:141–7.
32. Bosch JL, Hunink MG. The relationship between descriptive and valuational quality-of-life measures in patients with intermittent claudication. Med Dec Making 1996; 16:217–25.
33. Froberg DG, Kane RL. Methodology for measuring health-state preferences–II: scaling methods. J Clin Epidemiol 1989; 42:459–71.
34. Lenert LA, Cher DJ, Goldstein MK, Bergen MR, Garber A. The effect of search procedures on utility elicitations. Med Dec Making 1998; 18:76–83.
35. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987; 40:593.
36. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9:887–900.
37. Fischer G, Kamlet MS, Fienberg S, Schkade D. Risk preference for gains and losses in multiple objective decision making. Manage Sci 1986; 31:1065–86.
38. Hobart JC, Thompson AJ, Polman C, Hohlfeld R. Measuring health outcomes in multiple sclerosis: why, which and how? In Thompson AJ, Polman C, Hohlfeld, eds. Multiple Sclerosis: Clinical Challenges and Controversies. St. Louis: Mosby, 1997:211–26.
39. Feinstein AR. Clinimetrics. New Haven: Yale University Press, 1987.
40. Spector WD, Spilker B. Functional disability scales. In Quality of Life and Pharmacoeeconomics in Clinical Trials. Philadelphia: Lippincott Raven, 1996: 133–41.
41. Mowry EM, Beheshtian A, Waubant E, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009; 72:1760–5.
42. Miller DM, Cohen JA, Kooijmans M, Tsao E, Cutter G, Baier M. Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study. Mult Scler 2006; 12:180–6.
43. Cella D, Riley W, Stone A, et al. The patient-reported outcomes measurement information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol 2010; 63:1179–94.
44. Walker J, Hnke, JR, Cerny T, Strasser F. Development of symptom assessments utilising item response theory and computer-adaptive testing–a practical method based on a systematic review. Crit Rev Oncol-Hematol 2010; 73:47–67.
45. Bjorner JB, Chang C-H, Thissen D, Reeve BB. Developing tailored instruments: item banking and computerized adaptive assessment. Qual Life Res 2007; 16 Suppl 1:95–108.
46. Chang C-H. Patient-reported outcomes measurement and management with innovative methodologies and technologies. Qual Life Res 2007; 16 (Suppl 1):157–66.
47. Committee N-QE. Neuor-QoL: Progress report 2004–2007: NINDS, Evanston Northwestern Health Care, 2008.
48. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49:1237–42.
49. Hermann BP, Vickrey B, Hays RD, et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 1996; 25:113–18.
50. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life as a predictor for change in disability in MS. Neurology 2000; 55:51–4.
51. Shawaryn MA, Schiaffino KM, LaRocca NG, Johnston MV. Determinants of Health-Related Quality of Life in Multiple Sclerosis: The role of illness intrusiveness. Mult Scler 2002; 8:310–18.
52. Sugano DS, McElwee NE, Spilker B. An epidemiological perspective. In: Anonymous, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996:555–62.
53. Minden SL, Frankel D, Hadden LS, Srinath KP, Perloff JN. Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. Neurorehabilitation 2004; 19:55–67.
54. Wu N, Minden SL, Hoaglin DC, Hadden L, Frankel D. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Admin 2007; 30:233–67.
55. Quality AfHRa. Helping the Nation with Health Services Research. Rockville: US Department of Health and Human Services, 2002.
56. Spilker B. Introduction. In: Anonymous, ed. Quality of Life and Pharacoeconomics in Clinical Trials. Philadelphia, New York: Lippincott-Raven, 1996:1–10.
57. Miller D, Moore S, Fox R, et al. Web-based self-management for patients with multiple sclerosis: a practical randomized trial. Telemed e-Health 2010; 17: 5–13.
58. National Multiple Sclerosis S, Consortium of Multiple Sclerosis C. Multiple Sclerosis Quality of Life Inventory: A User's Manual. New York: National Multiple Sclerosis Society, 1997.
59. Rubenstein LV, Spilker B. Using quality of life tests for patient diagnosis or screening, or to evaluate treatment. In Spilker B, ed. Clinical Trials and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996:363–74.
60. Hays RD, Sherbourne CD, Bozzette SA, Spilker B. Pharmacoeconomics and quality of life research beyond the randomized clinical trial. In Spilker B, ed. Quality of Life Research and Pharamcoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996:155–60.
61. LaRocca NG, Ritvo PG, Miller DM, et al. Quality of life assessment in multiple sclerosis clinical trials: current status and strategies for improving multiple sclerosis clinical trial designs. In Goodkin DE, Rudick RA, eds. Multiple Sclerosis: Advances in Clinical Trial Design, Treatment and Future Perspectives. London: Springer, 1996:145–60.
62. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59:679–87.
63.Office of Communications DoDI, Center for Drug Evaluation and Research Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. In. Silver Spring, MD: Office of Communications, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 2009.
64. Miller DM, Allen R. Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice. Curr Neurol Neurosci Rep 2010; 10:397–406.
65. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4:187–206.
66. Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult Scler; 16:964–9.
67. McClurg D, Ashe RG, Marshall K, Lowe-Strong AS. Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 2006; 25:337–48.
68. Hart S, Fonareva I, Merluzzi N, Mohr DC. Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res 2005; 14:695–703.
69. Romberg A, Virtanen A, Ruutiainen J. Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. J Neurol 2005; 252:839–45.
70. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47:129–39.
71. McCullagh R, Fitzgerald AP, Murphy RP, Cooke G. Long-term benefits of exercising on quality of life and fatigue in multiple sclerosis patients with mild disability: a pilot study. Clin Rehabil 2008; 22:206–14.
72. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370:389–97.
73. Johnson SK, Diamond BJ, Rausch S, Kaufman M, Shiflett SC, Graves L. The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial. Explore: J Sci Healing 2006; 2:19–24.
74. Lankhorst GJ, Jelles F, Smits RC, et al. Quality of life in multiple sclerosis: the disability and impact profile (DIP). Neurol 1996; 243:469–74.
75. Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008; 71:1134–41.
76. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63:1788–95.
77. Rotstein Z, Barak Y, Noy S, Achiron A. Quality of life in multiple sclerosis: development and validation of the “RAYS” scale and comparison with the SF-36. Int J Qual Health Care 2000; 12:511–7.
78. Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001; 15:247–58.
79. Gold SM, Heesen C, Schulz H, et al. Disease specific quality of life instruments in multiple sclerosis: validation of the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS). Mult Scler 2001; 7:119–30.
80. Naseri M, Ahmadi A, Gharegozli K, et al. A double blind, placebo-controlled, crossover study on the effect of MS14, an herbal-marine drug, on quality of life in patients with multiple sclerosis. J Med Plant Res 2009; 3:271–5.
81. Schulz K-H, Gold SM, Witte J, et al. Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci 2004; 225:11–18.
82. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124:962–73.
83. Hughes CM, Smyth S, Lowe-Strong AS. Reflexology for the treatment of pain in people with multiple sclerosis: a double-blind randomised sham-controlled clinical trial. Mult Scler 2009; 15:1229–338.
84. McClurg D, Ashe RG, Lowe-Strong AS. Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis – a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn 2008; 27:231–7.
85. Khan F, Pallant JF, Brand C, Kilpatrick TJ. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79:1230–5.
86. Simeoni M, Auquier P, Fernandez O, et al. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Multiple Sclerosis 2008; 14:219–30.
87. Wynia K, Middel B, de Ruiter H, van Dijk JP, de Keyser JHA, Reijneveld SA. Stability and relative validity of the Multiple Sclerosis Impact Profile (MSIP). Disabil Rehabil 2008; 30:1027–38.
88. Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler 2009; 15:1092–102.
89. Wesson JM, Cooper JA, Jehle LS, Lockhart SN, Draney K, Barber J. The functional index for living with multiple sclerosis: development and validation of a new quality of life questionnaire. Mult Scler 2009; 15:1239–49.
90. Freeman JA, Thompson AJ, Fitzpatrick R, et al. Interferon-Beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology 2001; 57:1870–5.
91. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med 2006; 354:911–23.
92. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2006; 354:899–910.
93. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62:335–46.
94. Hobart J, Freeman J, Lamping D, Fitzpatrick R, Thompson A. The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry 2001; 71:363–70.
95. Freeman JA, Hobart JC, Langdon DW, Thompson AJ. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68:150–6.
96. Hickey AM, Bury G, O’Boyle CA, Bradley F, O’Kelly FD, Shannon W. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. BMJ 1996; 313:29–33.
97. Zingler VC, Nabauer M, Jahn K, et al. Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol 2005; 54:28–33.
98. Singer E. Tysabri withdrawal calls entire class into question. Nature Med 2005; 11:359.